TRENDING TOPICS
244 articles found for "savings"
The US Treasury announced plans to borrow $574 billion in Q1 2026 through its quarterly refunding, keeping auction sizes steady but leaning heavily on Treasury bills to finance America's growing debt.
Toyota will supply 400,000 battery packs annually from its North Carolina plant to Honda in an unprecedented deal designed to help both automakers avoid crippling tariffs.
Cigna reports adjusted Q4 EPS of $8.08, beating estimates, but 2026 guidance of $30.25 disappoints Wall Street as the insurer restructures its pharmacy benefits business.
The S&P Homebuilders Select Industry Index has gained 11% year-to-date, outpacing the broader market as falling mortgage rates and rising inventory create the most favorable conditions for builders since before the pandemic.
Texas Instruments announces $7.5 billion all-cash acquisition of Silicon Laboratories at a 69% premium, marking TI's largest deal since National Semiconductor in 2011.
Ford's $19.5 billion and GM's $6 billion EV-related writedowns signal a dramatic pivot as Detroit's electric vehicle ambitions meet consumer reluctance and mounting losses.
UBS reported Q4 profit of $1.2 billion, beating estimates by 31%, and announced $3 billion in share buybacks for 2026. Assets under management exceed $7 trillion for the first time.
Verizon stock jumps 3.6% to lead Dow Jones gains as new CEO Daniel Schulman's customer-focused strategy drives 616,000 postpaid phone additions and $25 billion buyback.
Merck delivered strong Q4 2025 results on Keytruda demand, but 2026 guidance disappointed investors as the pharmaceutical giant prepares for patent cliff challenges.
The longest yield curve inversion in financial history has ended without producing a recession, as the NY Fed puts recession probability at just 27% and falling.
More than half of S&P 500 companies are exceeding analyst estimates in Q4 2025, surpassing the historical 40% beat rate as Goldman Sachs projects 12% EPS growth for 2026.
Pfizer releases Q4 2025 earnings Tuesday morning as the pharmaceutical giant navigates life beyond COVID vaccines. Analysts expect $16.65 billion in revenue and $0.57 EPS.